Anyone researching Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) might want to consider the historical volatility of...
Pleased Involvement Catalyzed Much Needed Change at Merrimack and Intends to Continue to Monitor Situation LAKEWAY, Texas , Sept. 24, 2019 /PRNewswire/ -- JFL Capital Management, LLC (together with its ...
Merrimack Announces Sale Of Early Stage Asset for $2.25 Million And Provides Strategy Update.
Attorney and proxy fight expert Kai Liekefett estimated that upwards of 10 percent of public companies have faced activist investor challenges so far this year.
As the US$72m market cap Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) released another year of negative earnings...
Believes Significant Destruction of Value and Lack of Alignment with Stockholders Warrants an Overhaul in the Boardroom Highlights Potential Paths Forward to Unlock Stockholder Value that JFL Capital Nominees ...
Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) today announced its first quarter 2020 financial results for the period ended March 31, 2020.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, ...
Is Merrimack Pharmaceuticals Inc (NASDAQ:MACK) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before spending days of research on it. Given their 2 and 20 payment structure, hedge funds have more incentives and resources than the average investor. The funds […]
CAMBRIDGE, Mass., July 25, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced that its Board of Directors has authorized and declared a special cash dividend of $20 million on the Company's common stock. The special dividend is payable on September 5, 2019 to stockholders of record as of the close of business on August 28, 2019. The ex-dividend date for the special dividend will be September 6, 2019, the first trading day following the payment date.
CAMBRIDGE, Mass., May 30, 2019 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (MACK) today announced the completion of its review of strategic alternatives, following which the Company's Board of Directors is implementing a series of measures designed to extend Merrimack's cash runway into 2027 and preserve its ability to capture the potential remaining ONIVYDE-related milestones resulting from its 2017 asset sale to Ipsen S.A. The Company also announced plans to issue a special cash dividend. The core driver throughout the Company's strategic review process was to optimize value for shareholders, including through the preservation of potential milestone payments that Merrimack is eligible to receive.